# Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

> **NCT00415246** · PHASE3 · TERMINATED · sponsor: **Ipsen** · enrollment: 100 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)

## Key facts

- **NCT ID:** NCT00415246
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** The preliminary data do not support the expected sustainable blood levels of triptorelin for a duration of 4 months in all patients.
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415246, "Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00415246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*